Published: 10 June 2015

Publications

MARC's Remarks: March 2015 Meeting

This article is more than five years old. Some content may no longer be current.

Prescriber Update 36(2): 26
June 2015

The Medicines Adverse Reactions Committee (MARC) met on 12 March 2015 to consider:

• development of inhibitors to factor VIII replacement products (further information can be found in this edition of Prescriber Update¹)
• risk of cardiac arrhythmias with macrolide antibiotics (further information can be found in this edition of Prescriber Update²)
• cardiovascular risks associated with ibuprofen.

The MARC agreed that the ibuprofen data sheets should be harmonised so that information about cardiovascular risks is clear and consistent across all data sheets. In addition, the MARC recommended that Medsafe communicates information about cardiovascular risks to consumers and healthcare professionals.

Further information on this meeting can be found on the Medsafe website (www.medsafe.govt.nz/profs/adverse/Minutes161.htm).

References

1. Medsafe. 2015. Risk of inhibitor development with factor VIII replacement products. Prescriber Update 36(2): 21.
2. Medsafe. 2015. Macrolides — don’t upset the rhythm. Prescriber Update 36(2): 22.